Showing 1 – 2 of 2
Relevance | Newest | Oldest |
  • JAMA Original Investigation
    April 15, 2024

    Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban

    Wayne A.听Ray,听PhD; Cecilia P.听Chung,听MD, MPH; C. Michael听Stein,听MB, ChB; Walter听Smalley,听MD, MPH; Eli听Zimmerman,听MD; William D.听Dupont,听PhD; Adriana M.听Hung,听MD, MPH; James R.听Daugherty,听MS; Alyson听Dickson,听MA; Katherine T.听Murray,听MD
    Abstract Full Text
    is active quiz
    JAMA. 2024; 331(18):1565-1575. 10.1001/jama.2024.3867

    This cohort study assesses the association of diltiazem with risk of serious bleeding compared with metoprolol in older adults with atrial fibrillation receiving apixaban or rivaroxaban.

  • JAMA Original Investigation
    December 21, 2021

    Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation

    Wayne A.听Ray,听PhD; Cecilia P.听Chung,听MD, MPH; C. Michael听Stein,听MB, ChB; Walter听Smalley,听MD, MPH; Eli听Zimmerman,听MD; William D.听Dupont,听PhD; Adriana M.听Hung,听MD, MPH; James R.听Daugherty,听MS; Alyson听Dickson,听MA; Katherine T.听Murray,听MD
    Abstract Full Text
    free access is active quiz
    JAMA. 2021; 326(23):2395-2404. 10.1001/jama.2021.21222

    This cohort study assesses major ischemic and hemorrhagic outcomes in Medicare beneficiaries with atrial fibrillation who were treated with rivaroxaban compared with apixaban.